Key result
Frailty linked to ~109% greater mortality and hospitalization risk in older patients on HF medications.
Why the study?
Frailty is highly prevalent in heart failure and a major risk factor for adverse drug reactions and adverse drug events, but their prevalence, causality, and severity in frail compared with non-frail older adults remain to be described.
Do heart failure medications cause more adverse drug reactions and events in frail compared to non-frail older adults?
Systematic Review (n=2,596)
Do heart failure medications cause more adverse drug reactions and events in frail compared to non-frail older adults?
Frail older adults with heart failure have significantly higher risks of mortality and hospitalization, highlighting the need for frailty-specific pharmacovigilance and medication optimization.
Answers are grounded in this paper and cite their sources.
May warrant frailty-stratified monitoring in older HF patients; extends trial data on differential mortality risk.
INTRODUCTION: Frailty is highly prevalent in heart failure populations and a major risk factor for adverse drug reactions (ADRs) and adverse drug events (ADEs). This review aimed to describe the prevalence, causality and severity of ADRs or ADEs from heart failure medications among frail compared with non-frail older adults. METHODS: A systematic search of CENTRAL, MEDLINE, Embase, Ageline, CINAHL, International Pharmaceutical Abstracts, PsychInfo, Scopus, registries and citations prior to 18 May 2021 was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 checklist. Risk of bias and quality of evidence were assessed. Eligible studies included randomised controlled trials (RCTs) and observational studies of people diagnosed with heart failure, aged ≥ 65 years, with frailty defined by an objective measurement, and reported ADRs/ADEs from/with heart failure medications. RESULTS: Two reviewers screened 2419 articles; interrater reliability kappa = 0.88. Three observational studies (n = 2596), a secondary analysis of two RCTs (n = 2098) and two cohort studies (n = 498) were included in a narrative synthesis. Frail patients in randomised trials of sacubitril/valsartan, aliskiren, or enalapril had twice the risk of mortality (hazard ratio [HR] 2.09, 1.62-2.71) and hospitalisations (HR 1.82, 1.37-2.41) compared with robust patients, which may reflect responsiveness to medications and/or factors unrelated to medication use. Hospitalisations from falls, tiredness and nausea were probably attributable to digoxin and possibly preventable according to the Naranjo and Hallas scales, respectively. CONCLUSION: The potential harms from heart failure medications in frail older people are poorly studied and understood. Clinical trials and pharmacovigilance studies should include frailty as a covariate to inform medication optimisation for this vulnerable and growing population. REGISTRATION: Prospero registration number: CRD 42021253762.
No takes yet. Share an insight, caveat, or question.
Duong et al. (2022) conducted a systematic review in Heart failure in frail older adults (n=2,596). Heart failure medications (sacubitril/valsartan, aliskiren, enalapril, digoxin, ACEI/ARB) vs. Non-frail (robust) patients was evaluated on Mortality (HR 2.09, 95% CI 1.62-2.71). Frail older patients taking heart failure medications had approximately twice the risk of mortality (HR 2.09) and hospitalisations compared with robust patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: